PATENT CLAIM ANALYSIS

Application Number: 16088397
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-08
Patent Classification: ["544", "343000"]

Abstract:
The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Claim (Index 22):
The method according to  claim 13 , wherein the central nervous system disorder is residual symptoms of schizophrenia, delusional disorder, major depression with psychosis, bipolar disorder with psychotic symptoms, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder or psychosis caused by a medical condition or substance use.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 97.0
- Lexical Diversity: 1.30769
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14394467', '15629481', '14627968', '14777466', '16056143']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7979064159358006
- 35 USC 102 Novelty (BERT): 0.5471577619729
- Combined Prediction Score: 0.7728315505395105
- Mean Citation Score: 383.6470800000001
- Max Citation Score: 401.85004
- Similarity Product: 301.04345766853567

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test